Thor Åhlgren is proposed as a new board member in Auriant Mining AB (publ)

Written by Customer Service on December 12, 2022. Posted in Public Companies.

On December 9, 2022, Auriant Mining AB (publ) announced a notice to convene an extraordinary general meeting to be held on December 28, 2022. In the notice convening the general meeting, the Nomination Committee informed that it had nominated Thor Åhlgren to the Company’s Board of Directors. The Nomination Committee’s complete proposal on the election of a new board member will be published on the Company’s website by 14 December 2022. The Nomination Committee has decided to propose Thor Åhlgren, born 1997, as a new board member of Auriant Mining AB. Thor Åhlgren is a Swedish citizen and has a Master of Science in Applied Mathematics and a Bachelor of Science in Mechanical Engineering, both from the Royal Institute of Technology, Stockholm. Thor has previously worked with financial transactions involving mining companies...

16/2022・Supplementary Information to the Annual Report 2021

Written by Customer Service on December 12, 2022. Posted in Public Companies.

Company announcement no. 16 / 2022Schindellegi, Switzerland – 12 December 2022 Supplementary Information to the Annual Report 2021 With reference to company announcement no. 3/2022 dated 16 March 2022 as published by Trifork Holding AG (Swiss company registration number CHE-474.101.854) (“Trifork” or the “Company”) regarding the publication of the annual report for the financial year 2021, Trifork following dialogue with the Danish Business Authority today announces the publication of certain supplementary information relating to the Annual Report 2021. The supplementary information consists of a set of audited parent financial statements for 2021 prepared in accordance with IFRS as issued by the International Accounting Standards Board (“IASB”) and additional requirements according to the Danish Financial Statements Act as well...

UPDATE – Everything Blockchain Inc., Announces EB Build’s Debut on the AWS Marketplace

Written by Customer Service on December 12, 2022. Posted in Public Companies.

EB Build Revolutionizes the Blockchain and Database Industries Jacksonville, Florida, Dec. 12, 2022 (GLOBE NEWSWIRE) — Everything Blockchain Inc., (OTCMKTS: EBZT), a technology company that enables real-world use of blockchain to solve critical business issues, announced the debut of EB Build (EBB), a patent-pending solution that merges blockchain and database technologies, on the Amazon Web Services (AWS) Marketplace. “EBB is blazing the path for the rest of the blockchain industry, taking security and immutability to the next level and fusing this capability to a event-based database system.,” explained Cedric Harris, Chief Research Officer, Everything Blockchain, Inc. Typical blockchain architectures are public and permissionless and underpin crypto and similar projects. EBB is a different animal. It is a private, centralized,...

Baden Provides Update on Proposed Transaction With Northstar Gaming Inc.

Written by Customer Service on December 12, 2022. Posted in Mergers And Acquisitions.

VANCOUVER, British Columbia, Dec. 12, 2022 (GLOBE NEWSWIRE) — Baden Resources Inc. (CSE: BDN) (“Baden” or the “Company“) is pleased to provide an update on its previously announced proposed reverse-takeover (the “Proposed Transaction“) by NorthStar Gaming Inc. (“NorthStar“). Baden and NorthStar have agreed to amend the terms of their business combination to extend the outside date for completion of the Proposed Transaction to January 30, 2023. On November 23, 2022, Baden held an annual and special shareholders’ meeting at which all shareholder resolutions, including all shareholder resolutions necessary to complete the Proposed Transaction, were approved. Since the announcement of the Proposed Transaction, NorthStar has raised an aggregate of $10,075,000 in anticipation of completion...

Star8 Corp. Has moved and more

Written by Customer Service on December 12, 2022. Posted in Public Companies.

Tampa, Dec. 12, 2022 (GLOBE NEWSWIRE) — Star8 Corp. (OTCPK: STRH) is please to announce that the corporate headquarters has officially moved to the Tampa Urban Centre at Westshore, located at 4830 West Kennedy Blvd., Suite 600, Tampa, Florida, 33609. The facility allows us great flexibility for meeting and the ability to expand when it become necessary. Additionally, the headquarters is closer to Hyper 30 Data operations, which allows better control and management. Secondly, we are activity reviewing the qualifications of number of independent auditing firms, and I expect to announce the engagement within a few days. Completing an audit of our Company is important for two reasons, 1) to become a fully reporting entity, and 2) be up-listed OTCqb. Thirdly, our Company, through the acquisition of Hyper 30 Data is now focused on...

CNH Industrial’s new Electrification Center in Detroit, USA

Written by Customer Service on December 12, 2022. Posted in Public Companies.

Building capabilities and staying at the forefront of an important energy shift London, December 12, 2022 CNH Industrial announced during its Tech Day in Phoenix, Arizona, USA, that it has opened a new technical center in the Detroit Metro area of Michigan, USA. Designed to support our growing innovation in electrification, the center will enhance CNH Industrial’s technology capabilities. This is facilitated by its proximity to a nationwide hub for electrification OEMs and suppliers. “This new location underlines our commitment to growing our electric vehicle and subsystem profile, and marks yet another milestone after successfully expanding our in-house team,” said Marc Kermisch, Chief Digital and Information Officer and ad interim Chief Technology & Quality Officer, CNH Industrial. “Under one roof our team can now leverage cross-functional...

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

Written by Customer Service on December 12, 2022. Posted in Public Companies.

— Antileukemic activity demonstrated in patients with both relapsed/refractory and newly diagnosed AML — No evorpacept-related cytopenias observed and no maximum tolerated dose identified in combination with azacitidine and venetoclax — ALX Oncology to Host Conference Call on December 13th at 7:30 a.m. EST SOUTH SAN FRANCISCO, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint pathway, today announced the presentation of clinical data from the Phase 1a dose escalation part of the ASPEN-05 trial evaluating evorpacept in combination with azacitidine and venetoclax for the treatment of patients with relapsed or refractory (“r/r”) or newly diagnosed (“ND”) acute myeloid leukemia...

Keros Therapeutics Presents Clinical Data from its KER-050 and KER-047 Programs and Preclinical Data from its KER-050 and ALK2 Inhibitor Programs at the 64th American Society of Hematology Annual Meeting and Exposition

Written by Customer Service on December 12, 2022. Posted in Public Companies.

Keros Therapeutics will be hosting a conference call and webcast today, December 12, 2022, at 4:01 p.m. ET. LEXINGTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that it presented additional data from its ongoing Phase 2 clinical trial of KER-050 in patients with very low-, low-, or intermediate-risk myelodysplastic syndromes (“MDS”), as well as initial data from its ongoing Phase 2 clinical trial of KER-050 in patients with myelofibrosis (“MF”) and from its ongoing Phase 2 clinical trial of KER-047 in patients with iron-refractory iron...

<div>Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition</div>

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Written by Customer Service on December 12, 2022. Posted in Public Companies.

Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T cell differentiation which indicate therapeutic potential in Th2 and Th17-mediated autoimmune and allergic diseases Corvus confirms plans to initiate a Phase 2 clinical trial of CPI-818 in T cell lymphoma and a Phase 1 clinical trial in atopic dermatitis, both in 2023 Company to host conference call and webcast today at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced updated results from its Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, which demonstrated its anti-tumor activity in patients with T cell lymphoma (TCL) and its therapeutic potential in Th2...

Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

Written by Customer Service on December 12, 2022. Posted in Public Companies.

Activity of STAT3 degrader in preclinical model of cutaneous T-cell lymphoma (CTCL) validates selective STAT3 degradation as a potential therapeutic strategy for STAT3-driven T cell malignancies Preclinical study highlights the potential of IRAKIMiDs combined with BCL-2 inhibitor as a therapeutic approach for the treatment of MYD88-mutant diffuse large B-cell lymphoma (DLBCL) WATERTOWN, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that preclinical data from collaborations for its STAT3 and IRAKIMiD degraders was presented at the American Society of Hematology (ASH) Annual Meeting, taking place from December 10 – 13, 2022 in New Orleans,...

Day: December 12, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice